Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Current Assets (2017 - 2025)

Eton Pharmaceuticals' Current Assets history spans 8 years, with the latest figure at $60.6 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 47.68% to $60.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.6 million, a 47.68% increase, with the full-year FY2025 number at $60.6 million, up 47.68% from a year prior.
  • Current Assets hit $60.6 million in Q4 2025 for Eton Pharmaceuticals, down from $72.0 million in the prior quarter.
  • Over the last five years, Current Assets for ETON hit a ceiling of $72.0 million in Q3 2025 and a floor of $16.4 million in Q3 2022.
  • Historically, Current Assets has averaged $32.7 million across 5 years, with a median of $26.6 million in 2023.
  • Biggest five-year swings in Current Assets: plummeted 38.06% in 2022 and later surged 169.1% in 2025.
  • Tracing ETON's Current Assets over 5 years: stood at $23.6 million in 2021, then fell by 15.25% to $20.0 million in 2022, then surged by 34.17% to $26.8 million in 2023, then surged by 52.84% to $41.0 million in 2024, then skyrocketed by 47.68% to $60.6 million in 2025.
  • Business Quant data shows Current Assets for ETON at $60.6 million in Q4 2025, $72.0 million in Q3 2025, and $68.4 million in Q2 2025.